Astrazeneca PLC 6-K, filed Mar 31, 2020
Astrazeneca PLC (AZN)
6-K
2020-03-31
For: 2020-03-31
View Original
Added on
April 02, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on March 31, 2020.
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March
2020
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Director/PDMR
Shareholding
31 March 2020 07:00 BST
Transactions by Persons Discharging Managerial
Responsibilities
Disclosure under Article 19 of the EU Market Abuse
Regulation
AstraZeneca PLC (the Company) announced that, on 27 March 2020,
awards of the Company's ordinary shares of $0.25 each (Ordinary
Shares) vested to certain Persons Discharging Managerial
Responsibilities of the Company (PDMRs) under the AstraZeneca
Performance Share Plan (AZPSP).
The AZPSP award was granted on 27 March 2015 and was subject to a
three-year performance period followed by a two-year holding period
before vesting. Application of the performance measures specified
at the time of grant resulted in 77% of the AZPSP award vesting and
the remaining unvested part lapsing.
Following the withholding of shares to satisfy certain tax
obligations arising on vesting, the PDMRs' beneficial interests in
Ordinary Shares changed as detailed in the table
below:
|
PDMR
|
Ordinary Shares acquired under the AZPSP
|
|
Pascal
Soriot
|
74,698
|
|
Marc
Dunoyer
|
19,429
|
For tax purposes, the fair market value of an Ordinary Share at
vest was 6882 pence, being the closing price on the last trading
day preceding the vesting.
Further details are set out in the attached notifications, made in
accordance with the requirements of the EU Market Abuse
Regulation.
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
||
|
a)
|
Name
|
Pascal
Soriot
|
|
|
2
|
Reason for the notification
|
||
|
a)
|
Position/status
|
Chief
Executive Officer
|
|
|
b)
|
Initial notification /Amendment
|
Initial
notification
|
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
AstraZeneca
PLC
|
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
|
4i
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||
|
a)
|
Description of the financial instrument, type of
instrument
Identification
code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
|
|
b)
|
Nature of the transaction
|
Acquisition
of ordinary shares pursuant to a vesting under the AstraZeneca
Performance Share Plan, for nil consideration.
|
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
0
|
74,698
|
||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
|
|
e)
|
Date of the transaction
|
27
March 2020
|
|
|
f)
|
Place of the transaction
|
Outside
a trading venue
|
|
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
||
|
a)
|
Name
|
Marc
Dunoyer
|
|
|
2
|
Reason for the notification
|
||
|
a)
|
Position/status
|
Chief
Financial Officer
|
|
|
b)
|
Initial notification /Amendment
|
Initial
notification
|
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
AstraZeneca
PLC
|
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
|
4i
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||
|
a)
|
Description of the financial instrument, type of
instrument
Identification
code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
|
|
b)
|
Nature of the transaction
|
Acquisition
of ordinary shares pursuant to a vesting under the AstraZeneca
Performance Share Plan, for nil consideration.
|
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
0
|
19,429
|
||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
|
|
e)
|
Date of the transaction
|
27
March 2020
|
|
|
f)
|
Place of the transaction
|
Outside
a trading venue
|
|
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal and Metabolism, and Respiratory.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients
worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
31 March
2020
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|